ImCheck Appoints Stephan Braun as Chief Medical Officer
July 09, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
October 18, 2023 15:50 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
October 15, 2023 18:05 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 03, 2022 05:03 ET
|
ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01 EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
April 15, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET
|
ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
July 09, 2020 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer First hire in the US will support growing global business development activities Marseille, France, July 9, 2020 – ImCheck...